✦ LIBER ✦

Systemic morphine pharmacokinetics after ocular administration

✍ Scribed by F. Chast; C. Bardin; H. Sauvageon-Martre; S. Callaert; J.-C. Chaumeil

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 775 KB
Volume: 80
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.2600801002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of different epidural s

Pharmacokinetics of different epidural sites of morphine administration

✍ G. Nordberg; V. Hansdottir; L. Kvist; T. Mellstrand; T. Hedner 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 516 KB

Pharmacokinetic and pharmacodynamic stud

Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer

✍ Simin O. Mashayekhi; Mohammadreza Ghandforoush-Sattari; Philip A. Routledge; Ric 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

Pharmacokinetics of acetaminophen after

Pharmacokinetics of acetaminophen after intramuscular administration

✍ P. Macheras; M. Parissi-Poulos; L. Poulos 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

Isosorbide dinitrate: Pharmacokinetics a

Isosorbide dinitrate: Pharmacokinetics after intravenous administration

✍ R. A. Morrison; Ho-Leung Fung; D. Höhmann; T. Meinertz; E. Jähnchen 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB

Pharmacokinetics of cimetidine after sub

Pharmacokinetics of cimetidine after subchronic administration

✍ T. W. F. Chin; M. Spino; S. M. MacLeod; W. A. Mahon; S. J. Soldin 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 511 KB

Pharmacokinetics of carboplatin after in

Pharmacokinetics of carboplatin after intraperitoneal administration

✍ F. Elferink; W. J. F. Vijgh; I. Klein; W. W. Bokkel Huinink; R. Dubbelman; J. G. 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 455 KB

The pharmacokinetics of carboplatin, ultrafilterable platinum, and total platinum after intraperitoneal (i.p.) administration were studied in peritoneal fluid, plasma, red blood cells (RBCs), and urine during a phase-I trial in patients with minimal, residual ovarian cancer. Samples were collected f